TOP TEN perturbations for 39922_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39922_at
Selected probe(set): 207129_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39922_at (207129_at) across 6674 perturbations tested by GENEVESTIGATOR:

septic shock study 3 (D1; survivor) / normal blood sample

Relative Expression (log2-ratio):-2.1197329
Number of Samples:34 / 22
Experimental septic shock study 3 (D1; survivor)
Blood samples from patients (survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):2.0958061
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

septic shock study 3 (D3; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-1.8668184
Number of Samples:9 / 22
Experimental septic shock study 3 (D3; non-survivor)
Blood samples from patients (non-survivors) collected at day 3 (D3) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D2; survivor) / normal blood sample

Relative Expression (log2-ratio):-1.7817678
Number of Samples:12 / 22
Experimental septic shock study 3 (D2; survivor)
Blood samples from patients (survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D3; survivor) / normal blood sample

Relative Expression (log2-ratio):-1.749999
Number of Samples:22 / 22
Experimental septic shock study 3 (D3; survivor)
Blood samples from patients (survivors) collected at day 3 (D3) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D1; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-1.747304
Number of Samples:17 / 22
Experimental septic shock study 3 (D1; non-survivor)
Blood samples from patients (non-survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

adrenal gland cancer study 4 / normal adrenal cortex tissue

Relative Expression (log2-ratio):1.7338829
Number of Samples:43 / 4
Experimental adrenal gland cancer study 4
Primary tumor tissue samples of the adrenal cortex from patients with adrenocortical carcinoma (ACC).
Control normal adrenal cortex tissue
Histological normal adrenal gland cortical tissue samples derived after autopsy.

septic shock study 3 (D2; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-1.708992
Number of Samples:8 / 22
Experimental septic shock study 3 (D2; non-survivor)
Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

stem cell differentiation study 46 (BMP4, inhibitors) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):1.6130161
Number of Samples:3 / 3
Experimental stem cell differentiation study 46 (BMP4, inhibitors)
Extraembryonic cells differentiated from WA09 cells in chemically defined medium supplemented with BMP4 and inhibitors of activin and FGF2. Differentiation was performed in the absence of feeders cells and serum. Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then in CDM supplemented with BMP4 (10 ng/ml), an inhibitor of Alk4/5/7 receptors (type I Activin receptor-like kinase), SB431542 (10uM), and an inhibitor of FGF receptors, SU5402 (10uM), for 3-4 days.
Control normal embryonic stem cell sample (WA09)
WA09 embryonic stem cells cultivated in chemically defined medium (CDM). Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then further cultivated in CDM alone for 3-4 days. CDM consists of 50% Iscove’s Modified Dulbecco’s Medium and 50% F12 Ham´s nutrient mixture. It is devoid of serum and supplemented with insulin (7 ug/ml), transferrin (15 ug/ml), monothioglycerol (450 uM) and serum albumin (5 mg/ml).

glioma study 16 (LN-319) / normal astrocyte sample

Relative Expression (log2-ratio):1.4828167
Number of Samples:2 / 3
Experimental glioma study 16 (LN-319)
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.